成都看睾丸精索静脉曲张哪家医院好成都那里有治疗下肢动脉硬化的医院,成都治疗前列腺肥大哪里便宜,成都医院治老烂腿方法,成都粥样下肢动脉硬化去哪治,成都中医怎么治疗严重{静脉炎},成都婴儿血管瘤目前好的治疗方法,成都雷诺氏症治疗价钱

concerned about weaker economic growth being a reality for most advanced economies."Further mis-steps from European and US policymakers risk converting the cracks in their economies into a much deeper global system crisis which would have worrying economic and?social consequences," he warned.But Smith, whose bank is focusing on Asia to drive profit growth, remains optimistic for the outlook in the Asia-Pacific region.He said that the fact is that Australia is incredibly well positioned because of the nation's linkage to Asia, which remains the best performing part of the global economy.His comments came after ANZ reported a 1.45 billion U.S. dollars underlying profit for the June quarter, up 1.3 percent compared to the March quarter.

SAN FRANCISCO, Sept. 13 (Xinhua) -- Researchers in San Francisco, U.S. have found in a latest study that bisphenol A (BPA) and methylparaben, two chemicals commonly used in consumer products, can interfere with the breast cancer drugs, local media reported on Tuesday.In the study, doctors from California Pacific Medical Center in San Francisco found that healthy breast cells from high-risk patients started to find ways to bypass breast cancer drugs after they were exposed to BPA and methylparaben in the lab.The cells exposed to the two chemicals kept growing and didn't die after they were introduced with Tamoxifen, a current standard drug therapy for female breast cancer and most common used treatment for male breast cancer, Dr. William Goodson, lead author of the study, told San Francisco Chronicle.Goodson said that BPA and methylparaben not only mimic estrogen 's ability to drive cancer, but appear to be even better than the natural hormone in bypassing the ability of drugs to treat it. The finds have been published online in the British medical journal Carcinogenesis.The research shows more evidence of safety issues of BPA, a chemical primarily used to make plastic baby bottles, food containers, household electronics and etc, as well as the less known methylparaben, a chemical preservative used in cosmetics and other personal care products.The researchers noted that the breast cancer rates have been growing by about the same amount in men as in women over the past three decades. Scientists have been looking at environmental causes for the disease and wondering where the hormones are coming from.Goodson said BPA and methylparaben are used so widely and even found in household dust, noting that it is still unknown whether the effects of exposure to the chemicals are reversible.Since 2008, several governments issued reports questioning the negative health effects of BPA, especially raising concerns regarding exposure of fetuses, infants and children. BPA use has been banned in baby bottles in a lot of countries and regions.As for methylparaben, the U.S. Food and Drug Administration said on its website that "at the present time there is no reason for consumers to be concerned about the uses of cosmetics containing parabens (including methylparaben)."

BEIJING, July 14 (Xinhuanet) -- European music service Spotify is set to launch in the United States on Thursday, according to media reports.The streaming service will be available in the morning by invitation and through subscription."Spotify is a new way to listen to and manage your music, discover new tracks and share songs and playlists with friends – music whenever you want it, wherever you are," the company said in a statement.Spotify's streaming music and subscription service have long been popular in Europe since its launch in late 2008, and the company has been aiming for a US launch for nearly as long.Spotify has inked agreements with Sony Corp Music Entertainment, EMI Music, and Vivendi SA's Universal Music Group in the last few months. It is expected to close a deal with Warner Music Group by launch or soon after, according to a source.

TOKYO, Sept. 23 (Xinhua) -- Japan's H-2A rocket carrying a new information gathering satellite was launched at the Tanegashima Space Center in Kagoshima Prefecture on Friday, local media reported.Japan has already introduced three information-gathering satellites in the wake of a missile launch by Democratic People's Republic of Korea, and the latest one will replace the No. 2 satellite which has passed its use-by date, Kydo News said.Japan's H-2A rocket lifts off from the launchiung pad at the Tanegashima space centre in Kagoshima prefecture, Japan's southern island of Kyushu on September 23, 2011. Japan launched a new spy satellite into orbit September 23, officials saidThe development cost of the fourth satellite has reached 35.9 billion yen and its launch expenses have come to 10.4 billion yen, according to the government.The Japan Aerospace Exploration Agency and Mitsubishi Heavy Industries Ltd. were forced to put off the launch three times during the past four weeks due to the approach of a powerful typhoon and discovery of a system glitch. The rocket was initially scheduled to be sent into orbit on Aug. 28.

LOS ANGELES, June 5 (Xinhua) -- A latest study has found no evidence that screening for ovarian cancer may reduce the risk of dying from the disease, it was reported on Sunday.Screening, however, does increase the likelihood of unnecessary invasive procedures, according to researchers at the University of Utah.The researchers presented their findings at an on-going meeting of the American Society of Clinical Oncology in Chicago, The Los Angeles Times said.Researchers studied 78,216 women, ages 55 to 74, who participated in the National Cancer Institute's Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Half of the women received the usual care from their OB-gyns, and half received a CA 125 screening every year for six years and an ultrasound every year for four years. They were then followed for a maximum of 12 years.The researchers observed 212 ovarian cancers in the screened group and 176 in the normal care group. There were 118 ovarian cancer deaths in the screened group and 100 in the normal care group. The differences were not statistically significant. Overall, there were 2,924 deaths from all causes in the screened group and 2,914 in the normal care group.But the researchers also observed that 3,285 women had false- positive diagnoses from the screening. Among those, 1,080 underwent surgery that included an oophorectomy (surgical removal of one or both ovaries). Fifteen percent of those who had surgery developed major complications as a result. Overall, 1,771 women in the screened group (7.7 percent) had an oophorectomy, compared with 1,304 in the normal care group (5.8 percent)."We conclude that annual screening for ovarian cancer ... does not reduce disease-specific mortality in women at average risk for ovarian cancer but does increase invasive medical procedures and associated harms," the researchers said in the study.New data presented at the meeting also showed that the widely used cancer drug Avastin can improve treatment of ovarian cancer, The Times said.About 21,880 American women are diagnosed with ovarian cancer each year and about 13,850 die from it, according to the American Cancer Society. Because it produces few symptoms, the disease is typically not diagnosed until it has become advanced and spread throughout the body. As a result, five-year survival is only about 30 percent, and the disease is one of the five most deadly cancers among women. Being able to detect the cancer at an earlier stage when it might be more curable could thus, theoretically, improve the survival rate.The tests most commonly used to detect ovarian cancer include a transvaginal ultrasound to look for tumor masses and a blood test that screens for increased levels of a tumor marker called CA 125.